Successful treatment of pulmonary artery sarcoma by a two-drug combination chemotherapy consisting of ifosfamide and epirubicin

Akiko Uchida, Masahiro Tabata, Katsuyuki Kiura, Yasushi Tanimoto, Arihiko Kanehiro, Motoi Aoe, Nobuya Ohohara, Hiroshi Ueoka, Mitsune Tanimoto

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)

Abstract

We describe a case of 63-year-old woman with pulmonary artery sarcoma successfully treated with chemotherapy. She developed acute shortness of breath, and left chest and shoulder pain. Although a diagnosis of acute pulmonary embolism was made at a local hospital and she received anticoagulation and thrombolysis therapy, no improvement was achieved. Thereafter, she underwent a pulmonary thromboectomy in our hospital, and the histological diagnosis was intimal sarcoma of the pulmonary artery. Since post-operative computed tomography (CT) scans of the chest showed obvious persistence of an intraluminal hypoattenuated area in the left main pulmonary artery, the patient was treated with four cycles of a doublet chemotherapy consisting of ifosfamide (2.5 g/m2/day) on days 1-5 and epirubicin (45 mg/m2/day) on days 2 and 3. CT scans of the chest after four cycles showed marked regression of the intraluminal hypoattenuated area in the left main pulmonary artery. This is the first case of pulmonary artery sarcoma responding to chemotherapy. Surgical resection is currently the most hopeful treatment for pulmonary artery sarcoma. However, intensive chemotherapy is worth trying in unresectable patients.

Original languageEnglish
Pages (from-to)417-419
Number of pages3
JournalJapanese journal of clinical oncology
Volume35
Issue number7
DOIs
Publication statusPublished - Jul 2005

Keywords

  • Chemotherapy
  • Intimal sarcoma
  • Pulmonary artery

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'Successful treatment of pulmonary artery sarcoma by a two-drug combination chemotherapy consisting of ifosfamide and epirubicin'. Together they form a unique fingerprint.

Cite this